Funded Tech Companies
Antabio
Headquartered in Labège, Antabio has funding from BNP Paribas Développement, European Innovation Council Fund and AMR Action Fund.
Company Overview
Company Name
Antabio
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
436 Rue Pierre et Marie Curie
Labège, 31670
FR
Labège, 31670
FR
Phone
Website
Email Address
Company Background Information
Overview
Antabio is a privately-held clinical-stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments for drug-resistant infections due to CDC and WHO critical priority pathogens. The company has a particular focus on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases. Antabio's lead program, MEM-ANT3310, is being developed for the treatment of hospital-acquired infections such as nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE).
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
12/12/2023
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Marc Lemonnier
Company Investors
- BNP Paribas Développement
- European Innovation Council Fund
- AMR Action Fund
- Turenne
- Private Investors (Christophe Ricard)
Browse more funded tech companies:
Ant Money | Antares Advanced Test Technologies
Share this article
About Our Venture Capital Database
The company data above is provided by VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs